rs1557045267
Variant summary
Our verdict is Likely pathogenic. Variant got 5 ACMG points: 6P and 1B. PM2_SupportingBP4PS3_SupportingPP4_Strong
This summary comes from the ClinGen Evidence Repository: The NM_005629.4(SLC6A8):c.1171C>T (p.Arg391Trp) variant in SLC6A8 is a missense variant predicted to cause substitution of Tryptophan for Arginine at amino acid 391 (p.Arg391Trp). There is a ClinVar entry for this variant (Variation ID:465141, Conflicting Interpretations) with classifications as Pathogenic (n=2) and as a Variant of Uncertain Significance (n=1). This variant is absent from gnomAD v2.1.1, therefore PM2_Supporting criteria is applicable. The computational predictor REVEL gives a score of 0.078 which is below the threshold of 0.20, suggesting a benign effect of this variant on protein function, therefore BP4 criteria is applicable. The p.Arg391Trp variant has been reported in a male with intellectual disability, speech delay, and seizures who had biochemical studies including elevated Creatine:Creatinine ratio in urine and MRS demonstrating reduced Creatine peak in brain (Patient 2; [PMID:21910234]), which meets criteria for PP4_Strong. The patient from Mencarelli, 2011 [PMID:21910234] was also found to have the c.1171C>T (p.Arg391Trp) variant de novo, meeting criteria for PS2. Site directed mutagenesis and creatine uptake studies were performed with the p.Arg391Trp variant, and these studies demonstrated creatine uptake <10% wildtype cells (<150 μM creatine used), meeting PS3_Supporting criteria [PMID:30885608]. This variant has also been identified in a male with intellectual disability and/or seizures but without biochemical evidence of creatine transporter deficiency (elevated urine creatine:creatine, MRS demonstrating reduced creatine peak) [PMID:16738945], and given the absence of biochemical evidence of Creatine Transporter Deficiency in this individual evidence for pathogenicity was not scored. In summary, this variant meets the criteria to be classified as Likely Pathogenic for Creatine Transporter Deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PP4_Strong, PS2, PS3_Supporting, PM2_Supporting, BP4. Classification changed from VUS to LP given the only benign/conflicting evidence for this variant is in silico evidence. Using the new point scoring system from Tavtigian et.al 2020 [PMID:32720330], this variant meets criteria for Likely Pathogenic (Score: 4+4+1+1-1 = 9 points; Likely Pathogenic).(Classification approved by the CCDS VCEP Nov 10, 2022) LINK:https://erepo.genome.network/evrepo/ui/classification/CA415086241/MONDO:0010305/027
Frequency
Consequence
NM_005629.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC6A8 | NM_005629.4 | c.1171C>T | p.Arg391Trp | missense_variant | 8/13 | ENST00000253122.10 | NP_005620.1 | |
SLC6A8 | NM_001142805.2 | c.1141C>T | p.Arg381Trp | missense_variant | 8/13 | NP_001136277.1 | ||
SLC6A8 | NM_001142806.1 | c.826C>T | p.Arg276Trp | missense_variant | 8/13 | NP_001136278.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC6A8 | ENST00000253122.10 | c.1171C>T | p.Arg391Trp | missense_variant | 8/13 | 1 | NM_005629.4 | ENSP00000253122.5 |
Frequencies
GnomAD3 genomes Cov.: 25
GnomAD4 exome Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 1056214Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 343906
GnomAD4 genome Cov.: 25
ClinVar
Submissions by phenotype
Creatine transporter deficiency Pathogenic:4
Likely pathogenic, criteria provided, single submitter | clinical testing | Department of Genetics, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine | Mar 22, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 29, 2021 | For these reasons, this variant has been classified as Pathogenic. An experimental study has shown that this missense change disrupts the ability of the SLC6A8 protein to take up creatine in cell culture (PMID: 17465020). This variant has been reported in individuals affected with creatine transporter deficiency, including individuals in which the variant was found to be de novo (PMID: 16738945, 21910234, Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces arginine with tryptophan at codon 391 of the SLC6A8 protein (p.Arg391Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan. - |
Likely pathogenic, reviewed by expert panel | curation | ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen | Nov 10, 2022 | The NM_005629.4(SLC6A8):c.1171C>T (p.Arg391Trp) variant in SLC6A8 is a missense variant predicted to cause substitution of Tryptophan for Arginine at amino acid 391 (p.Arg391Trp). There is a ClinVar entry for this variant (Variation ID:465141, Conflicting Interpretations) with classifications as Pathogenic (n=2) and as a Variant of Uncertain Significance (n=1). This variant is absent from gnomAD v2.1.1, therefore PM2_Supporting criteria is applicable. The computational predictor REVEL gives a score of 0.078 which is below the threshold of 0.20, suggesting a benign effect of this variant on protein function, therefore BP4 criteria is applicable. The p.Arg391Trp variant has been reported in a male with intellectual disability, speech delay, and seizures who had biochemical studies including elevated Creatine:Creatinine ratio in urine and MRS demonstrating reduced Creatine peak in brain (Patient 2; [PMID:21910234]), which meets criteria for PP4_Strong. The patient from Mencarelli, 2011 [PMID:21910234] was also found to have the c.1171C>T (p.Arg391Trp) variant de novo, meeting criteria for PS2. Site directed mutagenesis and creatine uptake studies were performed with the p.Arg391Trp variant, and these studies demonstrated creatine uptake <10% wildtype cells (<150 μM creatine used), meeting PS3_Supporting criteria [PMID:30885608]. This variant has also been identified in a male with intellectual disability and/or seizures but without biochemical evidence of creatine transporter deficiency (elevated urine creatine:creatine, MRS demonstrating reduced creatine peak) [PMID:16738945], and given the absence of biochemical evidence of Creatine Transporter Deficiency in this individual evidence for pathogenicity was not scored. In summary, this variant meets the criteria to be classified as Likely Pathogenic for Creatine Transporter Deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PP4_Strong, PS2, PS3_Supporting, PM2_Supporting, BP4. Classification changed from VUS to LP given the only benign/conflicting evidence for this variant is in silico evidence. Using the new point scoring system from Tavtigian et.al 2020 [PMID:32720330], this variant meets criteria for Likely Pathogenic (Score: 4+4+1+1-1 = 9 points; Likely Pathogenic). (Classification approved by the CCDS VCEP Nov 10, 2022) - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics Lab, CHRU Brest | - | - - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 20, 2023 | The c.1171C>T (p.R391W) alteration is located in exon 8 (coding exon 8) of the SLC6A8 gene. This alteration results from a C to T substitution at nucleotide position 1171, causing the arginine (R) at amino acid position 391 to be replaced by a tryptophan (W). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been determined to be the result of a de novo mutation in multiple individuals with features consistent with SLC6A8-related cerebral creatine deficiency syndrome (Mencarelli, 2011; External communication) This amino acid position is not well conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). Functional studies suggest that overexpression of the p.R391W variant results in deficiency of creatine uptake in SLC6A8 deficient fibroblasts (Rosenberg, 2007; El-Kasaby, 2019). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as likely pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 30, 2019 | Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 30885608, 27081545, 15154114, 28065824, 15234334, 24190795, 10893433, 20846889, 23644449, 20528887, 21910234, 23408511, 16738945, 17465020, 24137762) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at